Cytostatic Action of Novel Histone Deacetylase Inhibitors in Androgen Receptor-Null Prostate Cancer Cells

Androgen receptor (AR)-null prostate tumors have been observed in 11–24% of patients. Histone deacetylases (HDACs) are overexpressed in prostate tumors. Therefore, HDAC inhibitors (Jazz90 and Jazz167) were examined in AR-null prostate cancer cell lines (PC3 and DU145). Both Jazz90 and Jazz167 inhibi...

Descripción completa

Detalles Bibliográficos
Autores principales: Rana, Zohaib, Tyndall, Joel D. A., Hanif, Muhammad, Hartinger, Christian G., Rosengren, Rhonda J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7912319/
https://www.ncbi.nlm.nih.gov/pubmed/33572730
http://dx.doi.org/10.3390/ph14020103

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7912319/
https://www.ncbi.nlm.nih.gov/pubmed/33572730
http://dx.doi.org/10.3390/ph14020103

Ejemplares similares